Biomarkers in congenital heart disease: do natriuretic peptides hold the key?

References

• Hoffman JI, Kaplan S. The incidence of congenital heart disease. J. Am. Coll. Cardiol. 39(12), 1890–1900 (2002).
   PubMed Web of Science ®Google Scholar
• van der Linde D, Konings EE, Slager MA et al. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. J. Am. Coll. Cardiol. 58(21), 2241–2247 (2011).
   PubMed Web of Science ®Google Scholar
• Oechslin EN, Harrison DA, Connelly MS, Webb GD, Siu SC. Mode of death in adults with congenital heart disease. Am. J. Cardiol. 86(10), 1111–1116 (2000).
   PubMed Web of Science ®Google Scholar
• Maisel AS, Krishnaswamy P, Nowak RM et al.; Breathing Not Properly Multinational Study Investigators. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N. Engl. J. Med. 347(3), 161–167 (2002).
   PubMed Web of Science ®Google Scholar
• Saremi A, Gopal D, Maisel AS. Brain natriuretic peptide-guided therapy in the inpatient management of decompensated heart failure. Expert Rev. Cardiovasc. Ther. 10(2), 191–203 (2012).
   PubMedGoogle Scholar
• Taub PR, Gabbai-Saldate P, Maisel A. Biomarkers of heart failure. Congest. Heart Fail. 16(Suppl. 1), S19–S24 (2010).
   Google Scholar
• Cohn JN, Levine TB, Olivari MT et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N. Engl. J. Med. 311(13), 819–823 (1984).
   PubMed Web of Science ®Google Scholar
• Pousset F, Isnard R, Lechat P et al. Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur. Heart J. 18(2), 254–258 (1997).
   PubMed Web of Science ®Google Scholar
• Sharma R, Bolger AP, Li W et al. Elevated circulating levels of inflammatory cytokines and bacterial endotoxin in adults with congenital heart disease. Am. J. Cardiol. 92(2), 188–193 (2003).
   PubMedGoogle Scholar
• Clark AL, Poole-Wilson PA, Coats AJ. Exercise limitation in chronic heart failure: central role of the periphery. J. Am. Coll. Cardiol. 28(5), 1092–1102 (1996).
   PubMed Web of Science ®Google Scholar
• Coats AJ. The ‘muscle hypothesis’ of chronic heart failure. J. Mol. Cell. Cardiol. 28(11), 2255–2262 (1996).
   PubMedGoogle Scholar
• Prieto LR, Hordof AJ, Secic M, Rosenbaum MS, Gersony WM. Progressive tricuspid valve disease in patients with congenitally corrected transposition of the great arteries. Circulation 98(10), 997–1005 (1998).
   PubMedGoogle Scholar
• Bolger AP, Sharma R, Li W et al. Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation 106(1), 92–99 (2002).
   PubMed Web of Science ®Google Scholar
• Clerico A, Recchia FA, Passino C, Emdin M. Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Am. J. Physiol. Heart Circ. Physiol. 290(1), H17–H29 (2006).
   PubMed Web of Science ®Google Scholar
• Baggish AL, van Kimmenade RR, Januzzi JL Jr. The differential diagnosis of an elevated amino-terminal pro-B-type natriuretic peptide level. Am. J. Cardiol. 101(3A), 43–48 (2008).
   PubMed Web of Science ®Google Scholar
• Almog Y, Novack V, Megralishvili R et al. Plasma level of N terminal pro-brain natriuretic peptide as a prognostic marker in critically ill patients. Anesth. Analg. 102(6), 1809–1815 (2006).
   PubMedGoogle Scholar
• Brueckmann M, Huhle G, Lang S et al. Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis. Circulation 112(4), 527–534 (2005).
   PubMed Web of Science ®Google Scholar
• Roch A, Allardet-Servent J, Michelet P et al. NH2 terminal pro-brain natriuretic peptide plasma level as an early marker of prognosis and cardiac dysfunction in septic shock patients. Crit. Care Med. 33(5), 1001–1007 (2005).
   PubMed Web of Science ®Google Scholar
• Yoshimura M, Yasue H, Okumura K et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 87(2), 464–469 (1993).
   PubMed Web of Science ®Google Scholar
• Cantinotti M, Storti S, Murzi B, Clerico A, Bibhuti BD. Clinical relevance of different B-type natriuretic peptide decisional cutoff values for the diagnosis of congenital heart disease in the first weeks of life. Pediatr. Cardiol. 32, 537–538 (2011).
   PubMedGoogle Scholar
• Law YM, Hoyer AW, Reller MD, Silberbach M. Accuracy of plasma B-type natriuretic peptide to diagnose significant cardiovascular disease in children: the Better Not Pout Children! Study. J. Am. Coll. Cardiol. 54(15), 1467–1475 (2009).
   PubMed Web of Science ®Google Scholar
• Lang Re, Unger T, Ganten D, Weil J, Bidlingmaier F, Dohlemann D. α atrial natriuretic peptide concentrations in plasma of children with congenital heart and pulmonary diseases. Br. Med. J. (Clin. Res. Ed.) 291(6504), 1241 (1985).
   PubMedGoogle Scholar
• Ishikawa S, Miyauchi T, Sakai S et al. Elevated levels of plasma endothelin-1 in young patients with pulmonary hypertension caused by congenital heart disease are decreased after successful surgical repair. J. Thorac. Cardiovasc. Surg. 110(1), 271–273 (1995).
   PubMed Web of Science ®Google Scholar
• Kikuchi K, Nishioka K, Ueda T et al. Relationship between plasma atrial natriuretic polypeptide concentration and hemodynamic measurements in children with congenital heart diseases. J. Pediatr. 111(3), 335–342 (1987).
   PubMedGoogle Scholar
• Suda K, Matsumura M, Matsumoto M. Clinical implication of plasma natriuretic peptides in children with ventricular septal defect. Pediatr. Int. 45(3), 249–254 (2003).
   PubMed Web of Science ®Google Scholar
• Iivainen TE, Groundstroem KW, Lahtela JT, Talvensaari TJ, Pasternack A, Uusitalo A. Serum N-terminal atrial natriuretic peptide in adult patients late after surgical repair of atrial septal defect. Eur. J. Heart Fail. 2(2), 161–165 (2000).
   PubMed Web of Science ®Google Scholar
• Tulevski II, Groenink M, van Der Wall EE et al. Increased brain and atrial natriuretic peptides in patients with chronic right ventricular pressure overload: correlation between plasma neurohormones and right ventricular dysfunction. Heart 86(1), 27–30 (2001).
   PubMed Web of Science ®Google Scholar
• Festa P, Ait-Ali L, Prontera C et al. Amino-terminal fragment of pro-brain natriuretic hormone identifies functional impairment and right ventricular overload in operated tetralogy of Fallot patients. Pediatr. Cardiol. 28(5), 339–345 (2007).
   PubMedGoogle Scholar
• Adrogué HJ, Madias NE. Hyponatremia. N. Engl. J. Med. 342(21), 1581–1589 (2000).
   PubMed Web of Science ®Google Scholar
• Anand IS, Ferrari R, Kalra GS, Wahi PL, Poole-Wilson PA, Harris PC. Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation 80(2), 299–305 (1989).
   PubMed Web of Science ®Google Scholar
• Upadhyay A, Jaber BL, Madias NE. Incidence and prevalence of hyponatremia. Am. J. Med. 119(7 Suppl. 1), S30–S35 (2006).
   PubMed Web of Science ®Google Scholar
• De Luca L, Orlandi C, Udelson JE, Fedele F, Gheorghiade M. Overview of vasopressin receptor antagonists in heart failure resulting in hospitalization. Am. J. Cardiol. 96(12A), 24L–33L (2005).
   Google Scholar
• Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N. Engl. J. Med. 356(20), 2064–2072 (2007).
   PubMed Web of Science ®Google Scholar
• LeJemtel TH, Serrano C. Vasopressin dysregulation: hyponatremia, fluid retention and congestive heart failure. Int. J. Cardiol. 120(1), 1–9 (2007).
   PubMed Web of Science ®Google Scholar
• Lilly LS, Dzau VJ, Williams GH, Rydstedt L, Hollenberg NK. Hyponatremia in congestive heart failure: implications for neurohumoral activation and responses to orthostasis. J. Clin. Endocrinol. Metab. 59(5), 924–930 (1984).
   PubMedGoogle Scholar
• Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N. Engl. J. Med. 341(8), 577–585 (1999).
   PubMed Web of Science ®Google Scholar
• Francis GS, Benedict C, Johnstone DE et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 82(5), 1724–1729 (1990).
   PubMed Web of Science ®Google Scholar
• Lee CR, Watkins ML, Patterson JH et al. Vasopressin: a new target for the treatment of heart failure. Am. Heart J. 146(1), 9–18 (2003).
   PubMed Web of Science ®Google Scholar
• Sanghi P, Uretsky BF, Schwarz ER. Vasopressin antagonism: a future treatment option in heart failure. Eur. Heart J. 26(6), 538–543 (2005).
   PubMedGoogle Scholar
• Dimopoulos K, Diller GP, Petraco R et al. Hyponatraemia: a strong predictor of mortality in adults with congenital heart disease. Eur. Heart J. 31(5), 595–601 (2010).
   PubMed Web of Science ®Google Scholar
• Diller GP, Dimopoulos K, Okonko D et al. Exercise intolerance in adult congenital heart disease: comparative severity, correlates, and prognostic implication. Circulation 112(6), 828–835 (2005).
   PubMed Web of Science ®Google Scholar
• Dimopoulos K, Diller GP, Piepoli MF, Gatzoulis MA. Exercise intolerance in adults with congenital heart disease. Cardiol. Clin. 24(4), 641–660, vii (2006).
   PubMed Web of Science ®Google Scholar
• Dimopoulos K, Okonko DO, Diller GP et al. Abnormal ventilatory response to exercise in adults with congenital heart disease relates to cyanosis and predicts survival. Circulation 113(24), 2796–2802 (2006).
   PubMed Web of Science ®Google Scholar
• Hasper D, Hummel M, Kleber FX, Reindl I, Volk HD. Systemic inflammation in patients with heart failure. Eur. Heart J. 19(5), 761–765 (1998).
   PubMedGoogle Scholar
• Ashraf SS, Tian Y, Zacharrias S, Cowan D, Martin P, Watterson K. Effects of cardiopulmonary bypass on neonatal and paediatric inflammatory profiles. Eur. J. Cardiothorac. Surg. 12(6), 862–868 (1997).
   PubMed Web of Science ®Google Scholar
• Seghaye M, Duchateau J, Bruniaux J et al. Interleukin-10 release related to cardiopulmonary bypass in infants undergoing cardiac operations. J. Thorac. Cardiovasc. Surg. 111(3), 545–553 (1996).
   PubMedGoogle Scholar
• Lequier LL, Nikaidoh H, Leonard SR et al. Preoperative and postoperative endotoxemia in children with congenital heart disease. Chest 117(6), 1706–1712 (2000).
   PubMedGoogle Scholar
• Casey WF, Hauser GJ, Hannallah RS, Midgley FM, Khan WN. Circulating endotoxin and tumor necrosis factor during pediatric cardiac surgery. Crit. Care Med. 20(8), 1090–1096 (1992).
   PubMed Web of Science ®Google Scholar
• Giannakoulas G, Dimopoulos K, Bolger AP et al. Usefulness of natriuretic peptide levels to predict mortality in adults with congenital heart disease. Am. J. Cardiol. 105(6), 869–873 (2010).
   PubMedGoogle Scholar
• Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 95(12), 2660–2667 (1997).
   PubMed Web of Science ®Google Scholar
• Mehra MR, Kobashigawa J, Starling R et al. Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates – 2006. J. Heart Lung Transplant. 25(9), 1024–1042 (2006).
   PubMed Web of Science ®Google Scholar
• Berger R, Huelsmann M, Strecker K et al. Neurohormonal risk stratification for sudden death and death owing to progressive heart failure in chronic heart failure. Eur. J. Clin. Invest. 35(1), 24–31 (2005).
   PubMedGoogle Scholar
• Hillege HL, Girbes AR, de Kam PJ et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 102(2), 203–210 (2000).
   PubMed Web of Science ®Google Scholar
• Vonder Muhll I, Liu P, Webb G. Applying standard therapies to new targets: the use of ACE inhibitors and B-blockers for heart failure in adults with congenital heart disease. Int. J. Cardiol. 97(Suppl. 1), 25–33 (2004).
   PubMedGoogle Scholar
• Alehan D, Ozkutlu S. Beneficial effects of 1-year captopril therapy in children with chronic aortic regurgitation who have no symptoms. Am. Heart J. 135(4), 598–603 (1998).
   PubMedGoogle Scholar
• Heragu N, Mahony L. Is captopril useful in decreasing pleural drainage in children after modified Fontan operation? Am. J. Cardiol. 84(9), 1109–1112, A10 (1999).
   PubMedGoogle Scholar
• Kouatli AA, Garcia JA, Zellers TM, Weinstein EM, Mahony L. Enalapril does not enhance exercise capacity in patients after Fontan procedure. Circulation 96(5), 1507–1512 (1997).
   PubMed Web of Science ®Google Scholar
• Dore A, Houde C, Chan KL et al. Angiotensin receptor blockade and exercise capacity in adults with systemic right ventricles: a multicenter, randomized, placebo-controlled clinical trial. Circulation 112(16), 2411–2416 (2005).
   PubMed Web of Science ®Google Scholar
• Hechter SJ, Fredriksen PM, Liu P et al. Angiotensin-converting enzyme inhibitors in adults after the Mustard procedure. Am. J. Cardiol. 87(5), 660–663, A11 (2001).
   PubMed Web of Science ®Google Scholar
• Lester SJ, McElhinney DB, Viloria E et al. Effects of losartan in patients with a systemically functioning morphologic right ventricle after atrial repair of transposition of the great arteries. Am. J. Cardiol. 88(11), 1314–1316 (2001).
   PubMed Web of Science ®Google Scholar
• Therrien J, Provost Y, Harrison J, Connelly M, Kaemmerer H, Webb GD. Effect of angiotensin receptor blockade on systemic right ventricular function and size: a small, randomized, placebo-controlled study. Int. J. Cardiol. 129(2), 187–192 (2008).
   PubMed Web of Science ®Google Scholar
• Tutarel O, Meyer GP, Bertram H, Wessel A, Schieffer B, Westhoff-Bleck M. Safety and efficiency of chronic ACE inhibition in symptomatic heart failure patients with a systemic right ventricle. Int. J. Cardiol. 154(1), 14–16 (2012).
   PubMedGoogle Scholar
• Buchhorn R, Hulpke-Wette M, Hilgers R, Bartmus D, Wessel A, Bürsch J. Propranolol treatment of congestive heart failure in infants with congenital heart disease: the CHF-PRO-INFANT trial. Congestive heart failure in infants treated with propanol. Int. J. Cardiol. 79(2–3), 167–173 (2001).
   PubMed Web of Science ®Google Scholar
• Buchhorn R, Bartmus D, Siekmeyer W, Hulpke-Wette M, Schulz R, Bürsch J. β-blocker therapy of severe congestive heart failure in infants with left to right shunts. Am. J. Cardiol. 81(11), 1366–1368 (1998).
   PubMedGoogle Scholar
• Buchhorn R, Hulpke-Wette M, Ruschewski W et al. Effects of therapeutic β blockade on myocardial function and cardiac remodelling in congenital cardiac disease. Cardiol. Young 13(1), 36–43 (2003).
   PubMedGoogle Scholar
• Buchhorn R, Ross RD, Hulpke-Wette M et al. Effectiveness of low dose captopril versus propranolol therapy in infants with severe congestive failure due to left-to-right shunts. Int. J. Cardiol. 76(2–3), 227–233 (2000).
   PubMedGoogle Scholar
• Doughan AR, McConnell ME, Book WM. Effect of β-blockers (carvedilol or metoprolol XL) in patients with transposition of great arteries and dysfunction of the systemic right ventricle. Am. J. Cardiol. 99(5), 704–706 (2007).
   PubMed Web of Science ®Google Scholar
• Giardini A, Lovato L, Donti A et al. A pilot study on the effects of carvedilol on right ventricular remodelling and exercise tolerance in patients with systemic right ventricle. Int. J. Cardiol. 114(2), 241–246 (2007).
   PubMed Web of Science ®Google Scholar
• Josephson CB, Howlett JG, Jackson SD, Finley J, Kells CM. A case series of systemic right ventricular dysfunction post atrial switch for simple D-transposition of the great arteries: the impact of β-blockade. Can. J. Cardiol. 22(9), 769–772 (2006).
   PubMed Web of Science ®Google Scholar
• Dimopoulos K. Trials and tribulations in adult congenital heart disease. Int. J. Cardiol. 129(2), 160–162 (2008).
   PubMedGoogle Scholar
• Jourdain P, Jondeau G, Funck F et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J. Am. Coll. Cardiol. 49(16), 1733–1739 (2007).
   PubMed Web of Science ®Google Scholar
• Kawai K, Hata K, Takaoka H, Kawai H, Yokoyama M. Plasma brain natriuretic peptide as a novel therapeutic indicator in idiopathic dilated cardiomyopathy during β-blocker therapy: a potential of hormone-guided treatment. Am. Heart J. 141(6), 925–932 (2001).
   PubMedGoogle Scholar
• McGeoch G, Lainchbury J, Town GI, Toop L, Espiner E, Richards AM. Plasma brain natriuretic peptide after long-term treatment for heart failure in general practice. Eur. J. Heart Fail. 4(4), 479–483 (2002).
   PubMed Web of Science ®Google Scholar
• Murdoch DR, McDonagh TA, Byrne J et al. Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am. Heart J. 138(6 Pt 1), 1126–1132 (1999).
   PubMed Web of Science ®Google Scholar
• Nicholls MG, Lainchbury JG, Richards AM, Troughton RW, Yandle TG. Brain natriuretic peptide-guided therapy for heart failure. Ann. Med. 33(6), 422–427 (2001).
   PubMed Web of Science ®Google Scholar
• Pfisterer M, Buser P, Rickli H et al.; TIME-CHF Investigators. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 301(4), 383–392 (2009).
   PubMed Web of Science ®Google Scholar
• Anand IS, Fisher LD, Chiang YT et al.; Val-HeFT Investigators. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107(9), 1278–1283 (2003).
   PubMed Web of Science ®Google Scholar
• Bettencourt P, Azevedo A, Pimenta J, Friões F, Ferreira S, Ferreira A. N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 110(15), 2168–2174 (2004).
   PubMed Web of Science ®Google Scholar
• Latini R, Masson S, Anand I et al.; Valsartan Heart Failure Trial Investigators. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 106(19), 2454–2458 (2002).
   PubMed Web of Science ®Google Scholar
• Masson S, Latini R, Anand IS et al.; Val-HeFT Investigators. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J. Am. Coll. Cardiol. 52(12), 997–1003 (2008).
   PubMed Web of Science ®Google Scholar
• Richards AM, Doughty R, Nicholls MG et al.; Australia–New Zealand Heart Failure Group. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. J. Am. Coll. Cardiol. 37(7), 1781–1787 (2001).
   PubMed Web of Science ®Google Scholar
• Richards AM, Lainchbury JG, Nicholls MG, Troughton RW, Yandle TG. BNP in hormone-guided treatment of heart failure. Trends Endocrinol. Metab. 13(4), 151–155 (2002).
   PubMedGoogle Scholar
• Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355(9210), 1126–1130 (2000).
   PubMed Web of Science ®Google Scholar
• Troughton RW, Richards AM, Nicholls MG. Individualized treatment of heart failure. Intern. Med. J. 31(3), 138–141 (2001).
   PubMedGoogle Scholar
• Clerico A, Fontana M, Ripoli A, Emdin M. Clinical relevance of BNP measurement in the follow-up of patients with chronic heart failure. Adv. Clin. Chem. 48, 163–179 (2009).
   PubMedGoogle Scholar
• Warnes CA, Williams RG, Bashore TM et al. ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease: Executive Summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines for the management of adults with congenital heart disease). Circulation 118(23), 2395–2451 (2008).
   PubMed Web of Science ®Google Scholar
• Niedner MF, Foley JL, Riffenburgh RH, Bichell DP, Peterson BM, Rodarte A. B-type natriuretic peptide: perioperative patterns in congenital heart disease. Congenit. Heart Dis. 5(3), 243–255 (2010).
   PubMedGoogle Scholar
• Hsu JH, Keller RL, Chikovani O et al. B-type natriuretic peptide levels predict outcome after neonatal cardiac surgery. J. Thorac. Cardiovasc. Surg. 134(4), 939–945 (2007).
   PubMed Web of Science ®Google Scholar
• Mir TS, Haun C, Lilje C, Läer S, Weil J. Utility of N-terminal brain natriuretic peptide plasma concentrations in comparison to lactate and troponin in children with congenital heart disease following open-heart surgery. Pediatr. Cardiol. 27(2), 209–216 (2006).
   PubMedGoogle Scholar
• Cantinotti M, Lorenzoni V, Storti S et al. Thyroid and brain natriuretic peptide response in children undergoing cardiac surgery for congenital heart disease–age-related variations and prognostic value. Circ. J. 77(1), 188–197 (2012).
   PubMedGoogle Scholar
• Book WM, Hott BJ, McConnell M. B-type natriuretic peptide levels in adults with congenital heart disease and right ventricular failure. Am. J. Cardiol. 95(4), 545–546 (2005).
   PubMed Web of Science ®Google Scholar
• Gatzoulis MA, Balaji S, Webber SA et al. Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot: a multicenter study. Lancet 356(9234), 975–981 (2000).
   PubMed Web of Science ®Google Scholar
• Gatzoulis MA, Till JA, Somerville J, Redington AN. Mechanoelectrical interaction in tetralogy of Fallot. QRS prolongation relates to right ventricular size and predicts malignant ventricular arrhythmias and sudden death. Circulation 92(2), 231–237 (1995).
   PubMed Web of Science ®Google Scholar
• Cheung EW, Lam WW, Chiu CS, Chau AK, Cheung SC, Cheung YF. Plasma brain natriuretic peptide levels, right ventricular volume overload and exercise capacity in adolescents after surgical repair of tetralogy of Fallot. Int. J. Cardiol. 121(2), 155–162 (2007).
   PubMedGoogle Scholar
• Dodge-Khatami A, Büchel EV, Knirsch W et al. Brain natriuretic peptide and magnetic resonance imaging in tetralogy with right ventricular dilatation. Ann. Thorac. Surg. 82(3), 983–988 (2006).
   PubMed Web of Science ®Google Scholar
• Hayabuchi Y, Matsuoka S, Kuroda Y. Plasma concentrations of atrial and brain natriuretic peptides and cyclic guanosine monophosphate in response to dobutamine infusion in patients with surgically repaired tetralogy of Fallot. Pediatr. Cardiol. 20(5), 343–350 (1999).
   PubMedGoogle Scholar
• Oosterhof T, Tulevski II, Vliegen HW, Spijkerboer AM, Mulder BJ. Effects of volume and/or pressure overload secondary to congenital heart disease (tetralogy of Fallot or pulmonary stenosis) on right ventricular function using cardiovascular magnetic resonance and B-type natriuretic peptide levels. Am. J. Cardiol. 97(7), 1051–1055 (2006).
   PubMedGoogle Scholar
• Norozi K, Buchhorn R, Bartmus D et al. Elevated brain natriuretic peptide and reduced exercise capacity in adult patients operated on for tetralogy of Fallot is due to biventricular dysfunction as determined by the myocardial performance index. Am. J. Cardiol. 97(9), 1377–1382 (2006).
   PubMedGoogle Scholar
• Oldershaw P, Bishop A. The difficulties of assessing right ventricular function. Br. Heart J. 74(2), 99–100 (1995).
   PubMedGoogle Scholar
• Voelkel NF, Quaife RA, Leinwand LA et al.; National Heart, Lung, and Blood Institute Working Group on Cellular and Molecular Mechanisms of Right Heart Failure. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation 114(17), 1883–1891 (2006).
   PubMed Web of Science ®Google Scholar
• Koch AM, Zink S, Singer H. B-type natriuretic peptide in patients with systemic right ventricle. Cardiology 110(1), 1–7 (2008).
   PubMedGoogle Scholar
• Nir A, Bar-Oz B, Perles Z, Brooks R, Korach A, Rein AJ. N-terminal pro-B-type natriuretic peptide: reference plasma levels from birth to adolescence. Elevated levels at birth and in infants and children with heart diseases. Acta Paediatr. 93(5), 603–607 (2004).
   PubMed Web of Science ®Google Scholar
• Kunii Y, Kamada M, Ohtsuki S et al. Plasma brain natriuretic peptide and the evaluation of volume overload in infants and children with congenital heart disease. Acta Med. Okayama 57(4), 191–197 (2003).
   PubMed Web of Science ®Google Scholar
• Hager A, Christov F, Hess J. Increase in N-terminus-pro-B-type natriuretic peptide during exercise of patients with univentricular heart after a total cavopulmonary connection. Pediatr. Cardiol. 33(5), 764–769 (2012).
   PubMedGoogle Scholar
• Law YM, Ettedgui J, Beerman L, Maisel A, Tofovic S. Comparison of plasma B-type natriuretic peptide levels in single ventricle patients with systemic ventricle heart failure versus isolated cavopulmonary failure. Am. J. Cardiol. 98(4), 520–524 (2006).
   PubMed Web of Science ®Google Scholar
• Lowenthal A, Camacho BV, Lowenthal S et al. Usefulness of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide as biomarkers for heart failure in young children with single ventricle congenital heart disease. Am. J. Cardiol. 109(6), 866–872 (2012).
   PubMed Web of Science ®Google Scholar
• Diller GP, Gatzoulis MA. Pulmonary vascular disease in adults with congenital heart disease. Circulation 115(8), 1039–1050 (2007).
   PubMed Web of Science ®Google Scholar
• Engelfriet P, Boersma E, Oechslin E et al. The spectrum of adult congenital heart disease in Europe: morbidity and mortality in a 5 year follow-up period. The Euro Heart Survey on adult congenital heart disease. Eur. Heart J. 26(21), 2325–2333 (2005).
   PubMed Web of Science ®Google Scholar
• Hopkins WE, Chen Z, Fukagawa NK, Hall C, Knot HJ, LeWinter MM. Increased atrial and brain natriuretic peptides in adults with cyanotic congenital heart disease: enhanced understanding of the relationship between hypoxia and natriuretic peptide secretion. Circulation 109(23), 2872–2877 (2004).
   PubMed Web of Science ®Google Scholar
• Hopkins WE, Hall C. Paradoxical relationship between N-terminal proatrial natriuretic peptide and filling pressure in adults with cyanotic congenital heart disease. Circulation 96(7), 2215–2220 (1997).
   PubMedGoogle Scholar
• Trojnarska O, Gwizdala A, Katarzynski S et al. The BNP concentrations and exercise capacity assessment with cardiopulmonary stress test in cyanotic adult patients with congenital heart diseases. Int. J. Cardiol. 139(3), 241–247 (2010).
   PubMedGoogle Scholar
• Haanwinckel MA, Elias LK, Favaretto AL, Gutkowska J, McCann SM, Antunes-Rodrigues J. Oxytocin mediates atrial natriuretic peptide release and natriuresis after volume expansion in the rat. Proc. Natl Acad. Sci. USA 92(17), 7902–7906 (1995).
   PubMed Web of Science ®Google Scholar
• Dimopoulos K, Inuzuka R, Goletto S et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation 121(1), 20–25 (2010).
   PubMed Web of Science ®Google Scholar
• Galiè N, Beghetti M, Gatzoulis MA et al.; Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 114(1), 48–54 (2006).
   PubMed Web of Science ®Google Scholar
• Diller GP, Alonso-Gonzalez R, Kempny A et al. B-type natriuretic peptide concentrations in contemporary Eisenmenger syndrome patients: predictive value and response to disease targeting therapy. Heart 98(9), 736–742 (2012).
   PubMed Web of Science ®Google Scholar
• Cantor WJ, Harrison DA, Moussadji JS et al. Determinants of survival and length of survival in adults with Eisenmenger syndrome. Am. J. Cardiol. 84(6), 677–681 (1999).
   PubMed Web of Science ®Google Scholar
• Daliento L, Somerville J, Presbitero P et al. Eisenmenger syndrome. Factors relating to deterioration and death. Eur. Heart J. 19(12), 1845–1855 (1998).
   PubMed Web of Science ®Google Scholar
• Diller GP, Dimopoulos K, Broberg CS et al. Presentation, survival prospects, and predictors of death in Eisenmenger syndrome: a combined retrospective and case–control study. Eur. Heart J. 27(14), 1737–1742 (2006).
   PubMed Web of Science ®Google Scholar
• Niwa K, Perloff JK, Kaplan S, Child JS, Miner PD. Eisenmenger syndrome in adults: ventricular septal defect, truncus arteriosus, univentricular heart. J. Am. Coll. Cardiol. 34(1), 223–232 (1999).
   PubMed Web of Science ®Google Scholar